WO2010120994A3 - Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse - Google Patents
Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse Download PDFInfo
- Publication number
- WO2010120994A3 WO2010120994A3 PCT/US2010/031183 US2010031183W WO2010120994A3 WO 2010120994 A3 WO2010120994 A3 WO 2010120994A3 US 2010031183 W US2010031183 W US 2010031183W WO 2010120994 A3 WO2010120994 A3 WO 2010120994A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kinase
- morpholino
- ureidoaryl
- carbamoylaryl
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Abstract
La présente invention concerne des composés d'uréido-phényl-morpholino pyrimidine et de guanidinophényl-morpholino pyrimidine de formule, et des procédés permettant de fabriquer les composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17032809P | 2009-04-17 | 2009-04-17 | |
US61/170,328 | 2009-04-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010120994A2 WO2010120994A2 (fr) | 2010-10-21 |
WO2010120994A3 true WO2010120994A3 (fr) | 2013-08-01 |
Family
ID=42983139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/031183 WO2010120994A2 (fr) | 2009-04-17 | 2010-04-15 | Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010120994A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112707907B (zh) * | 2019-10-24 | 2023-05-23 | 张飞 | 嘌呤衍生物及其中间体与制备抗癌症药物的应用 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2542536B1 (fr) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Dérivés d'urée à substitution morpholino en tant qu'inhibiteurs mTOR |
US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
JP2014510122A (ja) * | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | mTOR阻害剤としてのジヒドロピロロピリミジン誘導体 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
EP2758379B1 (fr) | 2011-09-21 | 2016-10-19 | Cellzome Limited | Dérivés d'urée et de carbamate de 2-morpholino-1,3,5-triazine en tant qu'inhibiteurs de mTOR pour le traitement de maladies immunologiques ou proliferatives |
BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
AU2012320465B2 (en) | 2011-10-07 | 2016-03-03 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9499561B2 (en) | 2012-04-10 | 2016-11-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
EP2970240B1 (fr) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
WO2014144169A1 (fr) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Inhibiteurs de carm1 et leurs utilisations |
EP3053926B1 (fr) | 2013-09-30 | 2018-08-08 | Shanghai Yingli Pharmaceutical Co. Ltd. | Composé de pyrimidine condensée, intermédiaire, procédé de préparation s'y rapportant et composition et application correspondantes |
EP3059238B1 (fr) * | 2013-10-16 | 2020-05-27 | Shanghai Yingli Pharmaceutical Co. Ltd. | Composé hétérocyclique condensé, son procédé de préparation, composition pharmaceutique et leurs utilisations |
RU2719422C2 (ru) | 2014-08-04 | 2020-04-17 | Нуэволюшон А/С | Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний |
CA3004534C (fr) * | 2015-11-23 | 2023-11-07 | Council Of Scientific & Industrial Research | Pyrimidines fusionnees utilisees comme inhibiteurs de la phosphoinositide 3-kinase alpha selectifs d'une isoforme et leur procede de preparation |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
CN107793365B (zh) * | 2016-08-31 | 2021-08-17 | 上海微创医疗器械(集团)有限公司 | 一种化合物及其制备方法和用途 |
SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
CN107721937B (zh) * | 2017-10-26 | 2021-02-05 | 沈阳药科大学 | 含有嘧啶酮骨架的化合物的制备方法和用途 |
CN108358949A (zh) * | 2018-03-01 | 2018-08-03 | 南京法恩化学有限公司 | 一种2,4-二氯噻吩并[3,2-d]嘧啶的制备方法 |
CN109824701B (zh) * | 2019-03-26 | 2021-08-13 | 武汉工程大学 | 一种吡啶并噻唑类化合物及其制备方法和应用 |
CA3160522A1 (fr) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Composes actifs vis-a-vis des recepteurs nucleaires |
CA3174176A1 (fr) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Composes actifs vis-a-vis des recepteurs nucleaires |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005914A1 (fr) * | 2004-07-09 | 2006-01-19 | Astrazeneca Ab | Pyrimidines a substitution triple aux positions 2, 4, 6 utilises en tant qu'inhibiteurs de phosphotidylinositol (pi) 3-kinase et utilisations de celles-ci pour traiter un cancer |
-
2010
- 2010-04-15 WO PCT/US2010/031183 patent/WO2010120994A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005914A1 (fr) * | 2004-07-09 | 2006-01-19 | Astrazeneca Ab | Pyrimidines a substitution triple aux positions 2, 4, 6 utilises en tant qu'inhibiteurs de phosphotidylinositol (pi) 3-kinase et utilisations de celles-ci pour traiter un cancer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112707907B (zh) * | 2019-10-24 | 2023-05-23 | 张飞 | 嘌呤衍生物及其中间体与制备抗癌症药物的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2010120994A2 (fr) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010120994A3 (fr) | Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse | |
WO2011031896A3 (fr) | Inhibiteurs de pi3 kinase et leurs utilisations | |
MX315904B (es) | Inhibidores de fosfoinosituro-3 cinasa. | |
IL220155B (en) | History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors | |
WO2010135524A8 (fr) | Inhibiteurs de pi3k/mtor à base de benzoxazépines pour lutter contre les maladies prolifératives | |
WO2011080568A8 (fr) | Nouveaux composés de pyrimidine en tant qu'inhibiteurs de mtor et p13k | |
ZA201100344B (en) | Pyrimidine derivatives as kinase inhibitors | |
TN2011000673A1 (en) | Bace inhibitors | |
HRP20130698T1 (en) | Novel phenylpyrazinones as kinase inhibitors | |
IL218271A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
SI2350071T1 (sl) | Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji | |
SI2350075T1 (sl) | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji | |
IL213906A0 (en) | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase | |
HK1172327A1 (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors jak3 | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
EP2211615A4 (fr) | Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase | |
WO2012071509A3 (fr) | Benzoxazépines utilisées comme inhibiteurs de p13k/mtor et procédés d'utilisation et de fabrication | |
EP2566477A4 (fr) | Amino-quinoléines en tant qu'inhibiteurs de kinase | |
ZA201201978B (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
PT2231642E (pt) | Pirimidinas como inibidores de quinase | |
WO2010068292A8 (fr) | Dérivés d'azaindole en tant qu'inhibiteurs de kinases | |
IL210573A0 (en) | Compounds as kinase inhibitors | |
IL218790A0 (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
AU2008203254A8 (en) | Compositions of phosphodiesterase type IV inhibitors | |
IL220205A0 (en) | Heterocyclic compounds as janus kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10765163 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10765163 Country of ref document: EP Kind code of ref document: A2 |